Upon initiation or discontinuation of guselkumab in patients who will be acquiring concomitant CYP450 substrates, specifically All those with a slim therapeutic index, consider monitoring for therapeutic effect. Contraindicated. The therapeutic effect of elbasvir/grazoprevir could possibly be min